Plant Name: Garcinia xanthochymus
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 4.531E-11 | 9.867E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.017E-07 | 6.570E-04 | HIF1A, LMNA, MTOR, OPRD1, TP53 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 5.313E-07 | 6.806E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 5.313E-07 | 6.806E-04 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.337E-07 | 6.806E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0097237; cellular response to toxic substance | 6.158E-07 | 7.450E-04 | APEX1, NFKB1, OPRD1, STAT6, TP53 |
| BP | GO:0009987; cellular process | GO:0006286; base-excision repair, base-free sugar-phosphate removal | 1.882E-06 | 1.576E-03 | APEX1, POLB |
| BP | GO:0009987; cellular process | GO:0008630; intrinsic apoptotic signaling pathway in response to DNA damage | 2.319E-06 | 1.629E-03 | EP300, MCL1, POLB, TP53 |
| MF | GO:0005488; binding | GO:0003684; damaged DNA binding | 2.185E-06 | 1.629E-03 | APEX1, EP300, POLB, TP53 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.552E-06 | 1.719E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0002039; p53 binding | 2.606E-06 | 1.719E-03 | EP300, HIF1A, HTT, TP53 |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.234E-06 | 2.634E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 5.640E-06 | 3.149E-03 | CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.127E-05 | 4.508E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0008134; transcription factor binding | 1.248E-05 | 4.669E-03 | APEX1, EP300, HIF1A, HTT, MTOR, NFKB1, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.416E-05 | 4.973E-03 | CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.819E-05 | 5.577E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019903; protein phosphatase binding | 2.083E-05 | 6.030E-03 | PTPN1, STAT6, TP53, VCP |
| BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 2.840E-05 | 7.349E-03 | ALOX15, CYP1A2, EP300, HIF1A, HTT, LMNA, MCL1, MTOR, PKM, POLB, SMN1, SMN2, THPO, TP53 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 2.869E-05 | 7.349E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0010035; response to inorganic substance | 3.500E-05 | 8.760E-03 | ALOX15, APEX1, CYP1A2, HIF1A, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:1903715; regulation of aerobic respiration | 3.934E-05 | 9.181E-03 | HIF1A, VCP |
| BP | GO:0009987; cellular process | GO:1902533; positive regulation of intracellular signal transduction | 3.963E-05 | 9.181E-03 | ALOX15, HTR2C, HTT, MCL1, MTOR, PTPN1, THPO, TP53 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 3.939E-05 | 9.181E-03 | HTT, MCL1, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53, VCP |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 4.039E-05 | 9.235E-03 | DRD3, HIF1A, MTOR |
| BP | GO:0008152; metabolic process | GO:0016579; protein deubiquitination | 4.107E-05 | 9.235E-03 | EP300, HIF1A, POLB, TP53, VCP |
| BP | GO:0008152; metabolic process | GO:0032787; monocarboxylic acid metabolic process | 4.283E-05 | 9.235E-03 | ALOX15, CYP1A2, CYP2C19, CYP2D6, HIF1A, PKM |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa00982 | Drug metabolism - cytochrome P450_Homo sapiens_hsa00982 | 3.210E-08 | 3.820E-06 | MAOA; CYP2D6; CYP1A2; CYP3A4; CYP2C19 |
| hsa00591 | Linoleic acid metabolism_Homo sapiens_hsa00591 | 6.112E-08 | 3.820E-06 | CYP1A2; ALOX15; CYP3A4; CYP2C19 |
| hsa04726 | Serotonergic synapse_Homo sapiens_hsa04726 | 3.683E-07 | 1.535E-05 | CYP2D6; MAOA; ALOX15; HTR2C; CYP2C19 |
| hsa04630 | Jak-STAT signaling pathway_Homo sapiens_hsa04630 | 2.026E-06 | 5.065E-05 | THPO; EP300; STAT6; MTOR; MCL1 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 1.905E-06 | 5.065E-05 | PKM; TP53; HIF1A; MTOR |
| hsa05215 | Prostate cancer_Homo sapiens_hsa05215 | 5.946E-06 | 1.239E-04 | EP300; TP53; NFKB1; MTOR |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 7.240E-06 | 1.293E-04 | POLB; PKM; EP300; TP53; NFKB1 |
| hsa04066 | HIF-1 signaling pathway_Homo sapiens_hsa04066 | 1.063E-05 | 1.661E-04 | EP300; HIF1A; NFKB1; MTOR |
| hsa04919 | Thyroid hormone signaling pathway_Homo sapiens_hsa04919 | 1.819E-05 | 2.527E-04 | EP300; TP53; HIF1A; MTOR |
| hsa04210 | Apoptosis_Homo sapiens_hsa04210 | 3.562E-05 | 4.452E-04 | LMNA; TP53; NFKB1; MCL1 |
| hsa05161 | Hepatitis B_Homo sapiens_hsa05161 | 4.197E-05 | 4.491E-04 | EP300; STAT6; TP53; NFKB1 |
| hsa05206 | MicroRNAs in cancer_Homo sapiens_hsa05206 | 4.311E-05 | 4.491E-04 | EP300; TP53; NFKB1; MTOR; MCL1 |
| hsa05200 | Pathways in cancer_Homo sapiens_hsa05200 | 1.692E-04 | 1.508E-03 | EP300; HIF1A; TP53; NFKB1; MTOR |
| hsa00980 | Metabolism of xenobiotics by cytochrome P450_Homo sapiens_hsa00980 | 1.281E-04 | 1.232E-03 | CYP2D6; CYP1A2; CYP3A4 |
| hsa04211 | Longevity regulating pathway - mammal_Homo sapiens_hsa04211 | 2.710E-04 | 2.117E-03 | TP53; NFKB1; MTOR |
| hsa05166 | HTLV-I infection_Homo sapiens_hsa05166 | 3.759E-04 | 2.764E-03 | POLB; EP300; TP53; NFKB1 |
| hsa04931 | Insulin resistance_Homo sapiens_hsa04931 | 4.187E-04 | 2.908E-03 | PTPN1; NFKB1; MTOR |
| hsa05204 | Chemical carcinogenesis_Homo sapiens_hsa05204 | 1.810E-04 | 1.508E-03 | CYP1A2; CYP3A4; CYP2C19 |
| hsa04151 | PI3K-Akt signaling pathway_Homo sapiens_hsa04151 | 1.069E-03 | 6.361E-03 | TP53; NFKB1; MTOR; MCL1 |
| hsa04071 | Sphingolipid signaling pathway_Homo sapiens_hsa04071 | 5.546E-04 | 3.649E-03 | OPRD1; TP53; NFKB1 |
| hsa05016 | Huntington's disease_Homo sapiens_hsa05016 | 2.182E-03 | 1.049E-02 | HTT; EP300; TP53 |
| hsa05169 | Epstein-Barr virus infection_Homo sapiens_hsa05169 | 2.483E-03 | 1.085E-02 | EP300; TP53; NFKB1 |
| hsa05205 | Proteoglycans in cancer_Homo sapiens_hsa05205 | 2.518E-03 | 1.085E-02 | TP53; HIF1A; MTOR |
| hsa05168 | Herpes simplex infection_Homo sapiens_hsa05168 | 1.934E-03 | 9.924E-03 | EP300; TP53; NFKB1 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 1.905E-03 | 9.924E-03 | PKM; MTOR |
| hsa00380 | Tryptophan metabolism_Homo sapiens_hsa00380 | 1.326E-03 | 7.536E-03 | MAOA; CYP1A2 |
| hsa01100 | Metabolic pathways_Homo sapiens_hsa01100 | 5.363E-03 | 1.596E-02 | PKM; MAOA; CYP1A2; ALOX15; CYP2C19; CYP3A4 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 2.676E-03 | 1.115E-02 | NFKB1; MTOR |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 1.985E-03 | 9.924E-03 | MAOA; NFKB1 |
| hsa05134 | Legionellosis_Homo sapiens_hsa05134 | 2.494E-03 | 1.085E-02 | VCP; NFKB1 |
| hsa04150 | mTOR signaling pathway_Homo sapiens_hsa04150 | 2.960E-03 | 1.156E-02 | HIF1A; MTOR |
| hsa05214 | Glioma_Homo sapiens_hsa05214 | 3.464E-03 | 1.174E-02 | TP53; MTOR |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 6.012E-03 | 1.708E-02 | OPRD1; HTR2C; DRD3 |
| hsa00590 | Arachidonic acid metabolism_Homo sapiens_hsa00590 | 3.157E-03 | 1.174E-02 | ALOX15; CYP2C19 |
| hsa05212 | Pancreatic cancer_Homo sapiens_hsa05212 | 3.569E-03 | 1.174E-02 | TP53; NFKB1 |
| hsa00830 | Retinol metabolism_Homo sapiens_hsa00830 | 3.464E-03 | 1.174E-02 | CYP1A2; CYP3A4 |
| hsa05220 | Chronic myeloid leukemia_Homo sapiens_hsa05220 | 4.348E-03 | 1.359E-02 | TP53; NFKB1 |
| hsa05211 | Renal cell carcinoma_Homo sapiens_hsa05211 | 3.569E-03 | 1.174E-02 | EP300; HIF1A |
| hsa05321 | Inflammatory bowel disease (IBD)_Homo sapiens_hsa05321 | 3.464E-03 | 1.174E-02 | STAT6; NFKB1 |
| hsa00140 | Steroid hormone biosynthesis_Homo sapiens_hsa00140 | 2.769E-03 | 1.117E-02 | CYP1A2; CYP3A4 |
| hsa03410 | Base excision repair_Homo sapiens_hsa03410 | 9.031E-04 | 5.644E-03 | POLB; APEX1 |
| hsa04922 | Glucagon signaling pathway_Homo sapiens_hsa04922 | 8.163E-03 | 2.171E-02 | PKM; EP300 |
| hsa05231 | Choline metabolism in cancer_Homo sapiens_hsa05231 | 8.163E-03 | 2.171E-02 | HIF1A; MTOR |
| hsa04920 | Adipocytokine signaling pathway_Homo sapiens_hsa04920 | 4.005E-03 | 1.284E-02 | NFKB1; MTOR |
| hsa05222 | Small cell lung cancer_Homo sapiens_hsa05222 | 5.982E-03 | 1.708E-02 | TP53; NFKB1 |
| hsa04722 | Neurotrophin signaling pathway_Homo sapiens_hsa04722 | 1.136E-02 | 2.959E-02 | TP53; NFKB1 |
| hsa04520 | Adherens junction_Homo sapiens_hsa04520 | 4.465E-03 | 1.361E-02 | PTPN1; EP300 |
| hsa04728 | Dopaminergic synapse_Homo sapiens_hsa04728 | 1.304E-02 | 3.260E-02 | MAOA; DRD3 |
| hsa05162 | Measles_Homo sapiens_hsa05162 | 1.442E-02 | 3.465E-02 | TP53; NFKB1 |
| hsa05160 | Hepatitis C_Homo sapiens_hsa05160 | 1.382E-02 | 3.387E-02 | TP53; NFKB1 |
| hsa04110 | Cell cycle_Homo sapiens_hsa04110 | 1.209E-02 | 3.085E-02 | EP300; TP53 |
| hsa04310 | Wnt signaling pathway_Homo sapiens_hsa04310 | 1.564E-02 | 3.621E-02 | EP300; TP53 |
| hsa04910 | Insulin signaling pathway_Homo sapiens_hsa04910 | 1.502E-02 | 3.543E-02 | PTPN1; MTOR |
| hsa00232 | Caffeine metabolism_Homo sapiens_hsa00232 | 6.732E-03 | 1.870E-02 | CYP1A2 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| I00-I99: Diseases of the circulatory system | Ischemic heart diseases | I20-I25 | OPRD1 |
| NA: NA | Acute nonspecific diarrhea | NA | OPRD1 |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TP53; TP53 |
| G00-G99: Diseases of the nervous system G00-G99 | Acute migraine | G43 | OPRD1 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Oral cavity cancer | C00-C08 | TP53 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Toxicity | T36-T50, T51-T65 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | OPRD1; HTR2C; CYP3A4; MAOA |
| C00-D49: Neoplasms | Aggressive non-hodgkin's lymphoma | C81, C81-C86, C82-C85, C91-C95 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | OPRD1; HTR2C; MAOA |
| NA: NA | Coronary artery restenosis | NA | MTOR |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Transplant rejection | D89.8, T86 | MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | DRD3 |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAOA |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Premature ejaculation | F52.4 | OPRD1 |
| C00-D49: Neoplasms | Hematological malignancies | C81-C86 | TP53 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Moderate-to-severe pain | R52, G89 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | HTR2C; MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | OPRD1; MTOR; HTR2C; PKM |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | MTOR |
| C00-D49: Neoplasms | Colorectal cancer | C18-C21 | TP53 |
| K00-K95: Diseases of the digestive system | Gastric motility disorder | K22.4 | DRD3 |
| C00-D49: Neoplasms | Multiple myeloma | C90 | VCP; MTOR; MTOR |
| C00-D49: Neoplasms | Overactive bladder disorder | C67, N32.81 | OPRD1 |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Organ rejection | D89.8, T86 | MTOR |
| NA: NA | Sleep initiation and maintenance disorders | NA | HTR2C |
| K00-K95: Diseases of the digestive system | Diarrhea-predominant IBS | K58.0 | OPRD1 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Drug abuse | F10-F19 | HTR2C; DRD3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Generalized anxiety disorder | F32, F40-F42, F41.1 | HTR2C |
| C00-D49: Neoplasms | Renal cancer | C64 | MTOR |
| C00-D49: Neoplasms | Ocular cancer | C69 | APEX1 |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cough | R05 | OPRD1 |
| C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | TP53 |
| H60-H95: Diseases of the ear and mastoid process | Hearing disorder | H90.5 | TP53 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | OPRD1; HTR2C; HTR2C; MAOA; MAOA |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; HTR2C; HTR2C |
| C00-D49: Neoplasms | Non-hodgkin's lymphoma | C85 | MTOR |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | MTOR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1; HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Depression | F30-F39 | HTR2C; MAOA |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Male sexual disorders | F52 | DRD3 |
| NA: NA | Chronic diarrhea associated with inflammatory bowel disease | NA | OPRD1 |
| G00-G99: Diseases of the nervous system G00-G99 | Spinal muscular atrophy | G00-G99 | SMN1;SMN2 |
| C00-D49: Neoplasms | Solid tumors | NA | MTOR |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | HIF1A; TP53; MTOR; PKM |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | MAOA |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | MAOA |
| C00-D49: Neoplasms | Sarcoma | C81-C86 | MTOR |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | OPRD1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | HTR2C |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | HTR2C |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | HTR2C; DRD3 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | HTR2C |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Dutch elm disease | B81-B83 | MTOR |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| N00-N99: Diseases of the genitourinary system | Urinary incontinence | N39.3, N39.4, R32 | OPRD1 |
| K00-K95: Diseases of the digestive system | Ulcerative colitis | K51 | MTOR |
| L00-L99: Diseases of the skin and subcutaneous tissue | Vitiligo | L80 | MAOA |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | MTOR |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD3 |
| C00-D49: Neoplasms | Cancer | C00-C96 | HIF1A; TP53; MTOR; NFKB1; MCL1 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MTOR |
| I00-I99: Diseases of the circulatory system | Renal artery disease | I70.1 | TP53 |
| C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | TP53 |
| NA: NA | Primary insomnia | NA | HTR2C |
| N00-N99: Diseases of the genitourinary system | Bladder disease | N30-N32 | OPRD1 |
| C00-D49: Neoplasms | Bladder cancer | C67 | MTOR |
| I00-I99: Diseases of the circulatory system | Pulmonary arterial hypertension | I27.0, I27.2 | HIF1A |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | HTR2C; DRD3 |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | HIF1A; MTOR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD3 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; NFKB1 |
| C00-D49: Neoplasms | Advanced kidney cancer | C64 | MTOR |